NASDAQ · CHSCL
Consumer Defensive · Agricultural Farm Products
$25.38
Down-$0.06 (-0.22%)
Updated Sep 16, 2026, 12:03 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CHSCL closed at $25.38 after 20 trading sessions, up 0.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $25.44 | $25.68 | $25.37 | $25.38 | 45.39K |
| Sep 14, 2026 | $25.49 | $25.599 | $25.391 | $25.435 | 20.83K |
| Sep 11, 2026 | $25.4599 | $25.47 | $25.38 | $25.47 | 21.44K |
| Sep 10, 2026 | $25.43 | $25.4599 | $25.36 | $25.38 | 13.49K |
| Sep 9, 2026 | $25.50 | $25.50 | $25.37 | $25.45 | 49.32K |
| Sep 8, 2026 | $25.41 | $25.48 | $25.40 | $25.45 | 25.12K |
| Sep 4, 2026 | $25.35 | $25.4595 | $25.35 | $25.40 | 25.53K |
| Sep 3, 2026 | $25.37 | $25.49 | $25.35 | $25.36 | 14.78K |
| Sep 2, 2026 | $25.45 | $25.47 | $25.36 | $25.3684 | 19.84K |
| Sep 1, 2026 | $25.435 | $25.54 | $25.34 | $25.35 | 29.93K |
| Aug 31, 2026 | $25.44 | $25.57 | $25.37 | $25.54 | 34.64K |
| Aug 28, 2026 | $25.51 | $25.51 | $25.32 | $25.3201 | 16.09K |
| Aug 27, 2026 | $25.405 | $25.62 | $25.36 | $25.50 | 19.33K |
| Aug 26, 2026 | $25.51 | $25.51 | $25.3501 | $25.3711 | 10.72K |
| Aug 25, 2026 | $25.355 | $25.50 | $25.35 | $25.40 | 28.52K |
| Aug 24, 2026 | $25.39 | $25.40 | $25.33 | $25.36 | 20.1K |
| Aug 21, 2026 | $25.39 | $25.40 | $25.3235 | $25.40 | 25.31K |
| Aug 20, 2026 | $25.29 | $25.43 | $25.29 | $25.37 | 16.52K |
| Aug 19, 2026 | $25.37 | $25.46 | $25.27 | $25.295 | 26.12K |
| Aug 18, 2026 | $25.335 | $25.39 | $25.2601 | $25.32 | 48.01K |
The latest Smart Investors Daily articles mentioning CHSCL.
CHSCL research
Company profile and research snapshot.
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
seekingalpha.com · Oct 1, 2025
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CHSCL.
No results
No recent SID articles mention CHSCL.
